CA3199586A1 - Antigen-binding molecules and uses thereof - Google Patents
Antigen-binding molecules and uses thereofInfo
- Publication number
- CA3199586A1 CA3199586A1 CA3199586A CA3199586A CA3199586A1 CA 3199586 A1 CA3199586 A1 CA 3199586A1 CA 3199586 A CA3199586 A CA 3199586A CA 3199586 A CA3199586 A CA 3199586A CA 3199586 A1 CA3199586 A1 CA 3199586A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid sequence
- seq
- antigen
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117383P | 2020-11-23 | 2020-11-23 | |
| US63/117,383 | 2020-11-23 | ||
| PCT/US2021/060369 WO2022109403A1 (en) | 2020-11-23 | 2021-11-22 | Antigen-binding molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3199586A1 true CA3199586A1 (en) | 2022-05-27 |
Family
ID=81709767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3199586A Pending CA3199586A1 (en) | 2020-11-23 | 2021-11-22 | Antigen-binding molecules and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230416356A1 (https=) |
| EP (1) | EP4247848A4 (https=) |
| JP (1) | JP2023550628A (https=) |
| KR (1) | KR20230118864A (https=) |
| CN (1) | CN116981691A (https=) |
| AU (1) | AU2021383841A1 (https=) |
| CA (1) | CA3199586A1 (https=) |
| WO (1) | WO2022109403A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4602073A2 (en) * | 2022-11-15 | 2025-08-20 | Purdue Research Foundation | Canine pd-l1 antibody, antigen binding fragments thereof, and methods of use thereof |
| GB202405576D0 (en) * | 2024-04-19 | 2024-06-05 | 272Bio Ltd | VHH antibodies |
| CN121362250A (zh) * | 2024-07-19 | 2026-01-20 | 普米斯生物技术(珠海)有限公司 | 抗il-31抗体、其药物组合物及用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03057B (me) * | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Molekuli humanizovanih antitela specifični za il-31 |
| WO2009138494A2 (en) * | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP2016522168A (ja) * | 2013-04-05 | 2016-07-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−４抗体及び二重特異性抗体及びその使用 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| JP6800853B2 (ja) * | 2014-12-11 | 2020-12-16 | ピエール、ファーブル、メディカマン | 抗ｃ１０ｏｒｆ５４抗体およびその使用 |
| GB201621439D0 (en) * | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| MX2020006105A (es) * | 2017-12-11 | 2020-11-09 | Ubi Ip Holdings | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. |
| CA3093539A1 (en) * | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| US11433139B2 (en) * | 2018-03-16 | 2022-09-06 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| WO2019183449A1 (en) * | 2018-03-23 | 2019-09-26 | North Carolina State University | Methods and compositions for allergic disorders |
| US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
-
2021
- 2021-11-22 WO PCT/US2021/060369 patent/WO2022109403A1/en not_active Ceased
- 2021-11-22 KR KR1020237020496A patent/KR20230118864A/ko active Pending
- 2021-11-22 JP JP2023530833A patent/JP2023550628A/ja active Pending
- 2021-11-22 US US18/037,938 patent/US20230416356A1/en active Pending
- 2021-11-22 EP EP21895765.2A patent/EP4247848A4/en active Pending
- 2021-11-22 CN CN202180091195.3A patent/CN116981691A/zh active Pending
- 2021-11-22 AU AU2021383841A patent/AU2021383841A1/en active Pending
- 2021-11-22 CA CA3199586A patent/CA3199586A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230416356A1 (en) | 2023-12-28 |
| KR20230118864A (ko) | 2023-08-14 |
| AU2021383841A1 (en) | 2023-06-22 |
| WO2022109403A1 (en) | 2022-05-27 |
| JP2023550628A (ja) | 2023-12-04 |
| AU2021383841A9 (en) | 2024-06-13 |
| EP4247848A4 (en) | 2025-10-01 |
| CN116981691A (zh) | 2023-10-31 |
| EP4247848A1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024205477A1 (en) | Anti-BCMA heavy chain-only antibodies | |
| JP5941049B2 (ja) | ヒトｔｗｅａｋに対する抗体およびその使用 | |
| JP2017500866A (ja) | イヌ化抗体 | |
| JP5596777B2 (ja) | ヒトｔｗｅａｋに対する抗体とその使用 | |
| US20230416356A1 (en) | Antigen-binding molecules and uses thereof | |
| KR20200131335A (ko) | 항-fam19a5 항체의 아데노-연관 바이러스(aav) 전달 | |
| KR20160099083A (ko) | 신규 항인간 bdca-2 항체 | |
| CA3194384A1 (en) | Caninized rat antibodies to canine interleukin-31 receptor alpha | |
| HK1207870A1 (en) | Anti-human sema4a antibodies useful to treat disease | |
| EP4514852A1 (en) | Single-chain fragment variable comprising mutant light chain framework region | |
| US20230110287A1 (en) | Antigen-binding molecules and uses thereof | |
| WO2023118241A1 (en) | Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof | |
| CN116410319A (zh) | 抗par2抗体及其用途 | |
| CN118638234B (zh) | 抗bdca2抗体及其制备方法和应用 | |
| US20250011412A1 (en) | Antigen-binding molecules and uses thereof | |
| CN114269788A (zh) | 一种能够与人4-1bb结合的分子及其应用 | |
| CN118667022A (zh) | 特异性结合人bdca2的抗体 | |
| KR20250050855A (ko) | Igf1r 항체 | |
| JP6529602B2 (ja) | 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体 | |
| US20260035484A1 (en) | Isolated antigen binding protein and use thereof | |
| RU2781301C2 (ru) | Анти-bcma антитела, содержащие только тяжёлую цепь | |
| JP2020506224A (ja) | ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法 | |
| HK40110110A (zh) | 具有经修饰的ch2-ch3序列的犬抗体 | |
| CN121991237A (zh) | 双特异性抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241025 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241025 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241025 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251110 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251110 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251121 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251121 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260119 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260119 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260120 |